Deal of the Week: Melinta/The Medicines Co.’s Antibiotics

As part of a previously announced restructuring plan, The Medicines Company (NASDAQ: MDCO) is selling its infectious disease business unit in order to double-down on its promising drug candidate, inclisiran. The drug is currently in Phase 3 development, and completion is expected in the second half of 2019. That’s a long way away, and MDCO […]

Werfen Life Divests to Focus on the Hemostasis Market

Some large and small healthcare players are shifting their portfolios to focus on the hemostasis analyzer market, which is expected to reach nearly $5 billion by 2021.